Do you know your PSMA-tracer? Variability in the biodistribution of different PSMA ligands and its potential impact on defining PSMA-positivity prior to PSMA-targeted therapy
Abstract Background In clinical practice, several radiopharmaceuticals are used for PSMA-PET imaging, each with distinct biodistribution patterns. This may impact treatment decisions and outcomes, as eligibility for PSMA-directed radioligand therapy is usually assessed by comparing tumoral uptake to...
Saved in:
Main Authors: | Jan Heilinger, Katrin Sabine Roth, Henning Weis, Antonis Fink, Jasmin Weindler, Felix Dietlein, Philipp Krapf, Klaus Schomäcker, Bernd Neumaier, Markus Dietlein, Alexander Drzezga, Carsten Kobe |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2025-01-01
|
Series: | EJNMMI Research |
Online Access: | https://doi.org/10.1186/s13550-024-01190-7 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PSMA Theranostics: Current Status and Future Directions
by: Kambiz Rahbar MD, et al.
Published: (2018-06-01) -
Pharmacokinetic and Biodistribution Assessment of a Near Infrared-Labeled PSMA-Specific Small Molecule in Tumor-Bearing Mice
by: Joy L. Kovar, et al.
Published: (2014-01-01) -
Gastric Adenocarcinoma Incidentally Detected by PET/CT with PSMA Ligands
by: Cesare Michele Iacovitti, et al.
Published: (2025-01-01) -
18 The role of PSMA expression in predicting aggressive disease phenotypes in patients with prostate cancer
by: G. Gandaglia, et al.
Published: (2025-01-01) -
6 Survival results of PSMA/PET-based salvage radiotherapy for recurrent prostate cancer
by: N. Grivas, et al.
Published: (2025-01-01)